VERALOX Therapeutics Inc.

VERALOX Therapeutics Inc. , based in Frederick, US, is focused on developing innovative therapies for immune-mediated diseases, including Heparin-Induced Thrombocytopenia (HIT) and Type 1 Diabetes (T1D). VERALOX Therapeutics Inc. was founded in 2018 in Frederick, US, specializing in therapies for immune-mediated diseases.

The company has successfully completed 3 deals, with its latest funding round being a SERIES A, raising USD 24. 000 mn on June 1, 2023, from investors including Genesys Capital Management and Sanofi Ventures. The founders, David Maloney, Jeffrey Strovel, and Matthew Boxer, have backgrounds in healthcare innovation. Jeffrey Strovel also serves as the current CEO of the firm.

Veralox Therapeutics develops therapies targeting immune-mediated diseases, with a lead product, VLX-1005, designed to inhibit 12-lipoxygenase (12-LOX). This product has received Orphan Designation and Fast Track Designation, indicating its potential significance. Veralox has also secured an exclusive agreement to acquire Nudge Therapeutics to enhance its product portfolio with novel cGAS inhibitors aimed at preventing Type 1 interferon overproduction. The company's offerings are mainly targeted at healthcare providers, research institutions, and pharmaceutical partners in North America and Europe.

Veralox Therapeutics generates revenue through partnerships and clinical trial collaborations, with plans to enter the market with VLX-1005 following successful trials, fully funded by the recent SERIES A financing of USD 24. 000 mn. This funding supports the Phase 2 clinical program for HIT treatment, with additional revenue expected from licensing agreements related to technologies from Nudge Therapeutics, structured through B2B partnerships with pharmaceutical firms and clinical research organizations. Following the recent SERIES A funding round, Veralox Therapeutics plans to utilize the USD 24.

000 mn to advance the Phase 2 clinical trial for VLX-1005, targeting Heparin-Induced Thrombocytopenia (HIT). The company is focusing on expanding its market presence in North America and Europe, with the aim of launching new products and enhancing its therapeutic offerings. The acquisition of Nudge Therapeutics is expected to bolster its portfolio with innovative solutions for Type 1 Diabetes, further addressing unmet medical needs.